Axonics (AXNX) Competitors $70.98 +0.53 (+0.75%) (As of 11/15/2024) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AXNX vs. SOLV, SNN, PEN, GKOS, BLCO, INSP, PRCT, NVST, NARI, and NVCRShould you be buying Axonics stock or one of its competitors? The main competitors of Axonics include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Envista (NVST), Inari Medical (NARI), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry. Axonics vs. Solventum Smith & Nephew Penumbra Glaukos Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics Envista Inari Medical NovoCure Axonics (NASDAQ:AXNX) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Which has preferable valuation and earnings, AXNX or SOLV? Solventum has higher revenue and earnings than Axonics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxonics$366.38M9.90-$6.09M-$0.12-591.45Solventum$8.26B1.45N/AN/AN/A Does the MarketBeat Community believe in AXNX or SOLV? Axonics received 173 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 66.41% of users gave Axonics an outperform vote while only 5.56% of users gave Solventum an outperform vote. CompanyUnderperformOutperformAxonicsOutperform Votes17466.41% Underperform Votes8833.59% SolventumOutperform Votes15.56%Underperform Votes1794.44% Do analysts prefer AXNX or SOLV? Axonics presently has a consensus price target of $71.00, indicating a potential upside of 0.03%. Solventum has a consensus price target of $68.29, indicating a potential downside of 1.83%. Given Axonics' higher probable upside, equities analysts plainly believe Axonics is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axonics 0 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Solventum 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders have more ownership in AXNX or SOLV? 99.5% of Axonics shares are held by institutional investors. 1.9% of Axonics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is AXNX or SOLV more profitable? Solventum has a net margin of 0.00% compared to Axonics' net margin of -1.31%. Axonics' return on equity of 0.36% beat Solventum's return on equity.Company Net Margins Return on Equity Return on Assets Axonics-1.31% 0.36% 0.31% Solventum N/A N/A N/A Does the media favor AXNX or SOLV? In the previous week, Solventum had 10 more articles in the media than Axonics. MarketBeat recorded 11 mentions for Solventum and 1 mentions for Axonics. Solventum's average media sentiment score of 1.13 beat Axonics' score of 0.00 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axonics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solventum 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAxonics beats Solventum on 8 of the 13 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Axonics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXNX vs. The Competition Export to ExcelMetricAxonicsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.63B$4.45B$5.28B$9.25BDividend YieldN/A52.58%5.21%4.00%P/E Ratio-591.4525.49108.7917.54Price / Sales9.9043.751,339.24143.53Price / Cash561.9657.1542.3538.50Price / Book5.647.414.884.88Net Income-$6.09M$13.70M$119.70M$225.52M7 Day PerformanceN/A0.20%17.70%-0.12%1 Month PerformanceN/A2.20%20.14%5.71%1 Year Performance19.25%55.89%37.79%21.36% Axonics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXNXAxonics2.3702 of 5 stars$70.98+0.8%$71.00+0.0%+22.3%$3.63B$366.38M-591.45610News CoverageHigh Trading VolumeSOLVSolventum1.4122 of 5 stars$70.66+1.0%$68.29-3.4%N/A$12.21BN/A0.0022,000Positive NewsSNNSmith & Nephew2.59 of 5 stars$25.93+2.2%N/A-4.6%$11.34B$5.55B0.0018,452News CoveragePENPenumbra4.1851 of 5 stars$240.18+1.2%$238.25-0.8%+2.2%$9.22B$1.06B276.774,200Analyst ForecastGKOSGlaukos4.0689 of 5 stars$137.45-2.0%$140.00+1.9%+129.8%$7.58B$314.71M-46.45780Analyst UpgradeInsider TradeShort Interest ↓News CoverageBLCOBausch + Lomb3.0508 of 5 stars$20.02-0.2%$21.00+4.9%+20.5%$7.05B$4.15B0.0013,300Analyst DowngradeShort Interest ↑News CoverageINSPInspire Medical Systems4.7633 of 5 stars$190.09-1.5%$233.58+22.9%+3.9%$5.70B$755.59M181.321,011Short Interest ↓Positive NewsPRCTPROCEPT BioRobotics2.0118 of 5 stars$94.84+1.3%$97.86+3.2%+120.1%$4.95B$136.19M0.00626NVSTEnvista3.7062 of 5 stars$19.93+0.2%$20.65+3.6%-18.2%$3.43B$2.57B-2.5612,800NARIInari Medical2.8309 of 5 stars$53.94+5.6%$58.89+9.2%-13.5%$3.16B$493.63M0.001,300Positive NewsNVCRNovoCure2.7316 of 5 stars$28.13+0.6%$30.33+7.8%+152.7%$3.04B$577.74M-19.971,453Analyst ForecastGap Up Related Companies and Tools Related Companies SOLV Competitors SNN Competitors PEN Competitors GKOS Competitors BLCO Competitors INSP Competitors PRCT Competitors NVST Competitors NARI Competitors NVCR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AXNX) was last updated on 12/14/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectCrypto 101 Media | SponsoredTrump won. Buy this coin now.Donald Trump just won the election resoundingly. And already, in the first few hours after the news, Bitcoi...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredWall Street Icon: “If you wait on this, it will already be too late”...Investing legend Louis Navellier warned us about the stock market crash of 1987... the 2000 dot-com crash… Enr...InvestorPlace | SponsoredSet Your Portfolio Up for Success in 2025…Set Your Portfolio Up for Success in 2025… Charles Payne’s beginner-friendly options strategies Unstoppable Prosperity | Sponsored$1 Trillion About to Get Wiped Out Because of this Sneaky Fed Move?The Federal Reserve is sitting on almost $1 TRILLION in unrealized losses. The reason why is that the Fed i...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axonics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axonics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
